NRIX vs. PAHC, AUPH, PRTC, SAGE, NUVB, WVE, COGT, CVAC, ANAB, and PRAX
Should you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Phibro Animal Health (PAHC), Aurinia Pharmaceuticals (AUPH), PureTech Health (PRTC), Sage Therapeutics (SAGE), Nuvation Bio (NUVB), Wave Life Sciences (WVE), Cogent Biosciences (COGT), CureVac (CVAC), AnaptysBio (ANAB), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical preparations" industry.
Nurix Therapeutics (NASDAQ:NRIX) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
In the previous week, Nurix Therapeutics had 17 more articles in the media than Phibro Animal Health. MarketBeat recorded 19 mentions for Nurix Therapeutics and 2 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.81 beat Nurix Therapeutics' score of 0.17 indicating that Phibro Animal Health is being referred to more favorably in the news media.
Phibro Animal Health has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Nurix Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
99.3% of Phibro Animal Health shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Phibro Animal Health received 255 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Nurix Therapeutics an outperform vote while only 59.92% of users gave Phibro Animal Health an outperform vote.
Phibro Animal Health has a net margin of 1.32% compared to Nurix Therapeutics' net margin of -178.93%. Phibro Animal Health's return on equity of 17.11% beat Nurix Therapeutics' return on equity.
Nurix Therapeutics currently has a consensus price target of $21.88, suggesting a potential upside of 31.86%. Phibro Animal Health has a consensus price target of $14.75, suggesting a potential downside of 19.84%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Phibro Animal Health.
Summary
Phibro Animal Health beats Nurix Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Nurix Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nurix Therapeutics Competitors List
Related Companies and Tools
